This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Looking back at 2023 , AI for drug discovery saw both wins and losses. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.
With the end of the year quickly approaching, you will likely see multiple articles on the key trends of 2023 and predictions for 2024 start popping up. A version of this article was previously published in the Journal of mHealth. Many of these will discuss the expanding role and capabilities of AI and machine learning in the Pharma space.
Pharmaceuticalmanufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.
Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcareproviders, and consumers alike face the need to quickly adapt.
The American Medical Association’s 2021-2023 Organizational Strategic Plan to Embed Racial Justice and Advance Health Equity In February 2021, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research issued new recommendations in five specific areas to broaden oncology trial eligibility criteria to include minorities.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content